Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer

BJU International

Volumn 115, Issue 5, 2015, Pages 744-752

  Oudard, Stéphane ^a   Kramer, Gero ^b   Caffo, Orazio ^c   Creppy, Lorraine ^d   Loriot, Yohan ^e   Hansen, Steinbjoern ^f   Holmberg, Mats ^g   Rolland, Frederic ^h   Machiels, Jean Pascal ⁱ   Krainer, Michael ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITY OF VIENNA   (Austria)

^c SANTA CHIARA HOSPITAL   (Italy)

^d INSTITUT BERGONIÉ   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h CENTRE RENÉ GAUDUCHEAU   (France)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

castration resistant; chemotherapy; docetaxel; prostate cancer

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; NAVELBINE; PLATINUM COMPLEX; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG RECHALLENGE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; CLINICAL TRIAL; EVALUATION STUDY; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REMISSION; RETREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REMISSION INDUCTION; RETREATMENT; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84927728212     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12845     Document Type: Article

References (42)

1. Tannock IF, de Wit R, Berry WR, et-al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512
2. Petrylak DP, Tangen CM, Hussain MH, et-al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245
4. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF, TAX 327 Investigators. Survival and PSA response of patients in TAX327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008; 19: 1749-1753
5. Oudard S, Banu E, Beuzeboc P, et-al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005; 23: 3343-3351
6. Horwich A, Hugosson J, de Reijke T, et-al. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013; 24: 1141-1162
7. Heidenreich A, Bastian PJ, Bellmunt J, et-al. EAU Guidelines on Prostate Cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-479
8. Cookson MS, Roth BJ, Dahm P, et-al. Castration-resistant prostate cancer: AUA guideline 2013. J Urol 2013; 190: 429-438
9. de Bono JS, Oudard S, Ozguroglu M, et-al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147-1154
10. Scher H, Fizazi K, Saad F, et-al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197
11. Fizazi K, Scher H, Molina A, et-al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992
12. Parker C, Nilsson S, Heinrich D, et-al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
13. Kantoff PW, Higano CS, Shore ND, et-al. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422
14. Tannock IF, Osoba D, Stockler MR, et-al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end-points. J Clin Oncol 1996; 14: 1756-1764
15. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM,. Multiple cycles of intermittent chemotherapy in metastatic androgen independent prostate cancer. Br J Cancer 2004; 91: 1425-1427
16. Beer TM, Ryan CW, Venner PM, et-al. Intermittent chemotherapy in patients with metastatic androgen independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008; 112: 326-330
17. Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J,. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008; 20: 891-896
18. Soga N, Kato M, Nishikawa K, et-al. Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol 2009; 14: 130-135
19. Eymard JC, Oudard S, Gravis G, et-al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106: 974-978
20. Di Lorenzo G, Buonerba C, Faiella A, et-al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011; 107: 234-239
21. Loriot Y, Massard C, Gross-Goupil M, et-al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010; 46: 1770-1772
22. Mountzios I, Bournakis E, Efstathiou E, et-al. Intermittent docetaxel chemotherapy in patients with castrate resistant prostate cancer. Urology 2011; 77: 682-687
23. Caffo O, Pappagallo G, Brugnara S, et-al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 2012; 79: 644-649
24. Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J,. Docetaxel in the treatment of metastatic castration resistant prostate cancer (mCRPC): an observational study in a single institution. Anticancer Res 2012; 32: 633-641
25. Heck M, Thalgott M, Retz M, et-al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int 2012; 110: E630-640
26. Scher HI, Halabi S, Tannock I, et-al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
27. Seruga B, Ocana A, Tannock IF,. Drug resistance in metastatic castration resistant prostate cancer. Nat Rev Clin Oncol 2011; 8: 12-23
28. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS,. Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat Rev Clin Oncol 2013; 10: 571-587
29. Toulmonde M, Madranges N, Brouste V, et-al. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity. Breast Cancer Res Treat 2012; 134: 325-332
30. Parmar MK, Ledermann JA, Colombo N, et-al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106
31. Zama IN, Hutson TE, Elson P, et-al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010; 116: 5400-5406
32. Heidenreich A, Bracarda S, Mason M, et-al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer (mCRPC): results of the European compassionate-use programme. Eur J Cancer 2014; 50: 1090-1099
33. Gan L, Chen S, Wang Y, et-al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69: 8386-8394
34. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N,. Tubulin-targeting chemotherapy impairs receptor activity in prostate cancer. Cancer Res 2010; 70: 7992-8002
35. Halabi S, Armstrong AJ, Sartor O, et-al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol 2013; 31: 3944-3950
36. Halabi S, Lin CY, Small EJ, et-al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013; 105: 1729-1737
37. Sweeney C, Chen YH, Carducci MA, et-al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone sensitive newly metastatic prostate cancer (mPrCa): an ECOG led phase III randomized trial. J Clin Oncol 2014; 32 (Suppl.): LBA2
38. Ryan CJ, Smith MR, de Bono JS, et-al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148
39. Beer TM, Armstrong AJ, Rathkopf DE, et-al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433
40. Mezynski J, Pezaro C, Bianchini D, et-al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943-2947
41. Pezaro CJ, Omlin AG, Altavilla A, et-al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2014; 66: 459-465
42. Al Nakouzi N, Le Moulec S, Albiges L, et-al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014 pii: S0302-2838(14)00396-0. [Epub ahead of print]. doi: 10.1016/j.eururo.2014.04.015